Please provide your email address to receive an email when new articles are posted on . Good vascular access continues to be a cornerstone of optimal hemodialysis (HD) for patients with end-stage ...

Please provide your email address to receive an email when new articles are posted on . Using data from the US Renal Data System, researchers identified 74,194 Medicare-eligible patients who initiated ...

Patients undergoing kidney dialysis with central venous catheters (CVCs) continue to have higher rates of bloodstream infections than those with other vascular access types, according to a new study.

The Food and Drug Administration (FDA) has approved DefenCath ® (taurolidine and heparin) catheter lock solution to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult ...

In contrast to reports of favorable survival in incident patients on peritoneal dialysis compared with hemodialysis, a recent study has shown similar survival outcome depending on type of vascular ...

BERKELEY HEIGHTS, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and ...

Long-term use of a topical antibiotic application at central venous catheter (CVC) exit sites in hemodialysis (HD) patients may result in a sustained decrease in all CVC-related infections, according ...

BERKELEY HEIGHTS, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening ...

This is the first FDA-approved antimicrobial catheter lock solution. The FDA has approved taurolidine plus heparin (DefenCath®) catheter lock solution to reduce catheter-related bloodstream infections ...

BERKELEY HEIGHTS, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention ...